

Substitute for form 1449A/PTO

JUN 07 2002

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/729,264
Filing Date:	11/28/2000
First Named Inventor	Welcher
Group Art Unit	1633-1635
Examiner Name	B. Whiteman

Sheet	1	of	1	Attorney Docket No.	01-668
-------	---	----	---	---------------------	--------

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
BW	EQ	WO	99/63088	A2	Genentech	12-09-1999	<del>crossed out</del>	
BM	ER	WO	00/36107	A2	Corixa Corp.	06-22-2000	<del>crossed out</del>	

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>

Examiner Signature	<i>Brian Whiteman</i>	Date Considered	12/23/02
--------------------	-----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231



#12

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3	Attorney Docket No.	01-668
-------	---	----	---	---------------------	--------

## Complete if Known

Application No.	09/729,264
Filing Date:	11/28/2000
First Named Inventor	Welcher
Group Art Unit	4633-1635
Examiner Name	B. Whiteman

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
PL	AA	3,773,919		Boswell et al.	11-20-1973
	AB	4,816,567		Cabilly et al.	03-28-1989
	AC	4,892,538		Aebischer et al.	01-09-1990
	AD	4,970,154		Chang	11-13-1990
	AE	5,011,472		Aebischer et al.	04-30-1991
	AF	5,106,627		Aebischer et al.	04-21-1992
	AG	5,593,875		Wurm et al.	01-14-1997
	AH	5,653,975		Baetge et al.	08-05-1997
	AI	5,676,954		Brigham	10-14-1997
PL	AJ	5,679,559		Kim et al.	10-21-1997

~~RECEIVED~~~~JUN 12 2002~~~~OFFICE OF PETITIONS~~

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PL	BA	EP	0 154 316	A2	Takeda Chemical Industries Ltd.	09-11-1985		
	BB	EP	0 401 384	A1	Kirin Amgen Inc.	12-12-1990		
	BC	EP	0 143 949	A1	Terumo Corp.	06-12-1985		
	BD	EP	0 036 676	A1	Univ. of California	09-30-1981		
	BE	EP	0 058 481	B1	Imperial Chemical Industries PLC	10-01-1986		
	BF	EP	0 088 046	A2	Ciba-Geigy AG	09-07-1983		
	BG	EP	0 133 988	A2	Hoechst AG	03-13-1985		
	BI	WO	91/10425	A1	Brown University Research Foundation	07-25-1991		
PL	BJ	WO	95/11308	A1	Amgen Inc.	04-27-1995		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

JUN 07 2002

	BK	WO	96/4095	A1	Baylor College of Medicine	12-19-1996	
--	----	----	---------	----	----------------------------	------------	--

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
DL	CA	ARUFFO <i>et al.</i> , "Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 84(23):8573-77 (1987).	
	CB	ALTSCHUL <i>et al.</i> , "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> 215(3):403-10 (1990).	
	CD	BRUNET <i>et al.</i> , "A New Member of the Immunoglobulin Superfamily - CTLA-4," <i>Nature</i> 328(6127):267-70 (1987).	
	DA	CARRILLO <i>et al.</i> , "The Multiple Sequence Alignment Problem in Biology," <i>SIAM J. Appl. Math.</i> 48(5):1073-82 (1988).	
	DB	DARIAVACH <i>et al.</i> , "Human Ig Superfamily CTLA-4 Gene: Chromosomal Localization and Identity of Protein Sequence between Murine and Human CTLA-4 Cytoplasmic Domains," <i>Eur. J. Immunol.</i> 18(12):1901-05 (1988).	
	DC	DAYHOFF <i>et al.</i> , "A Model of Evolutionary Change in Proteins," in <i>Atlas of Protein Sequence and Structure</i> , vol. 5, supp. 3 (1978).	
	DD	DEVEREUX <i>et al.</i> , "A Comprehensive Set of Sequence Analysis Programs for the VAX," <i>Nucleic Acids Res.</i> 12(1 Pt 1):387-95 (1984).	
	DE	ENGELS <i>et al.</i> , "Gene Synthesis," <i>Angew. Chem. Int'l. Ed. Engl.</i> 28:716-34 (1989).	
	DF	EPPSTEIN <i>et al.</i> , "Biological Activity of Liposome-Encapsulated Murine Interferon Gamma is Mediated by a Cell Membrane Receptor," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 82(11):3688-92 (1985).	
	DG	FRANCIS, "Protein Modification and Fusion Proteins," in <i>Focus on Growth Factors</i> , vol. 3, 4-10 (1992)	
	DH	FREEMAN <i>et al.</i> , "B7, a New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells," <i>J. Immunol.</i> 143(8):2714-22 (1989).	
	DI	FREEMAN <i>et al.</i> , "Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7," <i>J. Exp. Med.</i> 174(3):625-31 (1991).	
	DJ	FREEMAN <i>et al.</i> , "Murine B7-2, an Alternative CTLA4 Counter-Receptor that Costimulates T Cell Proliferation and Interleukin 2 Production," <i>J. Exp. Med.</i> 178(6):2185-92 (1993).	
	DK	FREEMAN <i>et al.</i> , "Cloning of B7-2: A CTLA-4 Counter-Receptor that Costimulates Human T Cell Proliferation," <i>Science</i> 262(5135):909-11 (1993).	
	DN	GROSS <i>et al.</i> , "The Murine Homologue of the T Lymphocyte Antigen CD28. Molecular Cloning and Cell Surface Expression," <i>J. Immunol.</i> 144(8):3201-10 (1990).	
	DQ	HOOGENBOOM <i>et al.</i> , "By-Passing Immunisation. Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged <i>in vitro</i> ," <i>J. Mol. Biol.</i> 227(2):381-88 (1992).	
	DR	HOUGHTON <i>et al.</i> , "General Method for the Rapid Solid-Phase Synthesis of Large Numbers of Peptides: Specificity of Antigen-Antibody Interaction at the Level of Individual Amino Acids," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 82:5131-35 (1985).	
	DS	HUTLOFF <i>et al.</i> , "ICOS is an Inducible T-Cell Co-Stimulator Structurally and Functionally Related to CD28," <i>Nature</i> 397(6716):263-66 (1999).	
	DT	JAKOBOVITS <i>et al.</i> , "Germ-Line Transmission and Expression of a Human-Derived Yeast Artificial Chromosome," <i>Nature</i> 362(6417):255-58 (1993).	
DL	DU	JAKOBOVITS <i>et al.</i> , "Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-Chain Joining Region Blocks B-Cell Development and Antibody Production," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90(6):2551-55 (1993).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

B M in New

12/21/02

12/23/03

Y	DV	JONES <i>et al.</i> , "Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse," <i>Nature</i> 321(6069):522-25 (1986).
	DW	KITTS <i>et al.</i> , "A Method for Producing Recombinant Baculovirus Expression Vectors at High Frequency," <i>Biotechniques</i> 14(5):810-17 (1993).
	DX	LANGER <i>et al.</i> , "Biocompatibility of Polymeric Delivery Systems for Macromolecules," <i>J. Biomed. Mater. Res.</i> 15(2):267-77 (1981).
	DY	LANGER, "Controlled Release of Macromolecules," <i>Chem. Tech.</i> 12:98-105 (1982).
	EB	LUCKOW, "Baculovirus systems for the expression of human gene products," <i>Curr. Opin. Biotechnol.</i> 4(5):564-72 (1993).
JUN 07 2002	EC	LUCKOW <i>et al.</i> , "Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in <i>Escherichia coli</i> ," <i>J. Virol.</i> 67(8):4566-79 (1993).
	ED	MARKS <i>et al.</i> , "By-passing immunization. Human antibodies from V-gene libraries displayed on phage," <i>J. Mol. Biol.</i> 222(3):581-97 (1991).
	EE	MARSTON <i>et al.</i> , "Solubilization of protein aggregates," <i>Methods Enzymol.</i> 182:264-76 (1990).
	EF	MACDONALD <i>et al.</i> , "Isolation of RNA using guanidinium salts," <i>Methods Enzymol.</i> 152:219-27 (1987).
	EG	MERRIFIELD, "Solid Phase Synthesis. I. The Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> 85:2149-54 (1963).
	EH	MORRISON <i>et al.</i> , "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 81(21):6851-55 (1984).
	EI	NEEDLEMAN <i>et al.</i> , "A general method applicable to the search for similarities in the amino acid sequence of two proteins," <i>J. Mol. Biol.</i> 48(3):443-53 (1970).
	EJ	OGDEN <i>et al.</i> , "Electrophoresis in agarose and acrylamide gels," <i>Methods Enzymol.</i> 152:61-87 (1987).
	EK	RIECHMANN <i>et al.</i> , "Reshaping human antibodies for therapy," <i>Nature</i> 332(6162):323-27 (1988).
	EM	SIDMAN <i>et al.</i> , "Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid," <i>Biopolymers</i> 22(1):547-56 (1983).
P	EP	VERHOYEN <i>et al.</i> , "Reshaping human antibodies: grafting an antilysozyme activity," <i>Science</i> 239(4847):1534-36 (1988).

Examiner Signature	Pn LK	Date Considered	12/23/03
--------------------	-------	-----------------	----------

\*EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231